Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment
Lung cancers, the number one cancer killer, can be broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being the most commonly diagnosed type. Anticancer agents for NSCLC suffer from various limitations that can be partly overcome by the application...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/14/3539 |
id |
doaj-0effdce13dfa4d18a1ef55bc26aa2b74 |
---|---|
record_format |
Article |
spelling |
doaj-0effdce13dfa4d18a1ef55bc26aa2b742021-07-23T13:33:41ZengMDPI AGCancers2072-66942021-07-01133539353910.3390/cancers13143539Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer TreatmentNoratiqah Mohtar0Thaigarajan Parumasivam1Amirah Mohd Gazzali2Chu Shan Tan3Mei Lan Tan4Rozana Othman5Siti Sarah Fazalul Rahiman6Habibah A. Wahab7School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, MalaysiaFaculty of Pharmacy, Universiti Malaya, Kuala Lumpur 50603, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, MalaysiaLung cancers, the number one cancer killer, can be broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being the most commonly diagnosed type. Anticancer agents for NSCLC suffer from various limitations that can be partly overcome by the application of nanomedicines. Nanoparticles is a branch within nanomedicine that can improve the delivery of anticancer drugs, whilst ensuring the stability and sufficient bioavailability following administration. There are many publications available in the literature exploring different types of nanoparticles from different materials. The effectiveness of a treatment option needs to be validated in suitable in vitro and/or in vivo models. This includes the developed nanoparticles, to prove their safety and efficacy. Many researchers have turned towards in vitro models that use normal cells or specific cells from diseased tissues. However, in cellular works, the physiological dynamics that is available in the body could not be mimicked entirely, and hence, there is still possible development of false positive or false negative results from the in vitro models. This article provides an overview of NSCLC, the different nanoparticles available to date, and in vitro evaluation of the nanoparticles. Different types of cells suitable for in vitro study and the important precautions to limit the development of false results are also extensively discussed.https://www.mdpi.com/2072-6694/13/14/3539non-small cell lung cancerdrug deliverynanoparticlespulmonarycellular uptakepermeability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Noratiqah Mohtar Thaigarajan Parumasivam Amirah Mohd Gazzali Chu Shan Tan Mei Lan Tan Rozana Othman Siti Sarah Fazalul Rahiman Habibah A. Wahab |
spellingShingle |
Noratiqah Mohtar Thaigarajan Parumasivam Amirah Mohd Gazzali Chu Shan Tan Mei Lan Tan Rozana Othman Siti Sarah Fazalul Rahiman Habibah A. Wahab Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment Cancers non-small cell lung cancer drug delivery nanoparticles pulmonary cellular uptake permeability |
author_facet |
Noratiqah Mohtar Thaigarajan Parumasivam Amirah Mohd Gazzali Chu Shan Tan Mei Lan Tan Rozana Othman Siti Sarah Fazalul Rahiman Habibah A. Wahab |
author_sort |
Noratiqah Mohtar |
title |
Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment |
title_short |
Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment |
title_full |
Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment |
title_fullStr |
Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment |
title_full_unstemmed |
Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment |
title_sort |
advanced nanoparticle-based drug delivery systems and their cellular evaluation for non-small cell lung cancer treatment |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-07-01 |
description |
Lung cancers, the number one cancer killer, can be broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being the most commonly diagnosed type. Anticancer agents for NSCLC suffer from various limitations that can be partly overcome by the application of nanomedicines. Nanoparticles is a branch within nanomedicine that can improve the delivery of anticancer drugs, whilst ensuring the stability and sufficient bioavailability following administration. There are many publications available in the literature exploring different types of nanoparticles from different materials. The effectiveness of a treatment option needs to be validated in suitable in vitro and/or in vivo models. This includes the developed nanoparticles, to prove their safety and efficacy. Many researchers have turned towards in vitro models that use normal cells or specific cells from diseased tissues. However, in cellular works, the physiological dynamics that is available in the body could not be mimicked entirely, and hence, there is still possible development of false positive or false negative results from the in vitro models. This article provides an overview of NSCLC, the different nanoparticles available to date, and in vitro evaluation of the nanoparticles. Different types of cells suitable for in vitro study and the important precautions to limit the development of false results are also extensively discussed. |
topic |
non-small cell lung cancer drug delivery nanoparticles pulmonary cellular uptake permeability |
url |
https://www.mdpi.com/2072-6694/13/14/3539 |
work_keys_str_mv |
AT noratiqahmohtar advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment AT thaigarajanparumasivam advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment AT amirahmohdgazzali advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment AT chushantan advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment AT meilantan advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment AT rozanaothman advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment AT sitisarahfazalulrahiman advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment AT habibahawahab advancednanoparticlebaseddrugdeliverysystemsandtheircellularevaluationfornonsmallcelllungcancertreatment |
_version_ |
1714430780954902528 |